AI Article Synopsis
- The study investigated the presence of GnRH receptors (GnRH-R) in uterine tissues, including leiomyomas, myometrium, and endometrium, and examined their relationship with estrogen and progesterone receptors.
- GnRH-R was found in all types of uterine tissues, with the highest occurrence in myometrium, but the lowest mean receptor content compared to leiomyoma and endometrium.
- The presence of GnRH-R in the endometrium appeared to depend on its levels in surrounding tissues, and its absence was linked to significantly higher levels of estrogen receptors.
Article Abstract
The present study evaluated the presence of GnRH-R in leiomyomas, in associated, non-involved uterine tissues (myometrium and endometrium) and the possible relationships between GnRH-R and the receptors for estrogen and progesterone in the same tissues. GnRH-R was found in all uterine tissues and both GnRH and the GnRH analog, goserelin, displaced its binding consistent with a single type of high affinity receptor (Kd approximate to 10(-8) M). GnRH-R were found more frequently in myometrium (81% of samples) than in endometrium (58%) or leiomyoma (42%). However, the mean receptor content was lowest in myometrium (139+/-19 fmol/mg protein) with both leiomyomas (288+/-77 fmol/mg protein) and endometrium (372+/-96 fmol/mg protein) having significantly higher values. Endometrial GnRH binding varied from 596+/-42 in uteri that were GnRH-R positive in the endothelium alone to 231+/-49 when GnRH-R was present also in the other tissues. Endometrium negative for the GnRH-R had significantly higher levels of estrogen receptor than all the other uterine samples (266+/-25 vs 61+/-7.5 fmol/mg protein, respectively). Endometrial GnRH-R seem to be dependent on its presence and/or level in other uterine tissues. Further, when GnRH-R is absent in the endometrium this tissue expresses greatly increased levels of steroid receptors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3892/ijo.11.3.603 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synthesis and in vitro evaluation of novel compounds and discovery of a promising iodine-125 radioligand for purinergic P2X7 receptor (P2X7R).
Bioorg Med Chem
February 2025
Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, United States. Electronic address:
The purinergic P2X ligand-gated ion channel 7 receptor (P2X7R) plays a critical role in various inflammatory processes and other diseases. Fast determination of compounds P2X7R binding potency and discovery of a promise PET radiotracer for imaging P2X7R require a P2X7R suitable radioligand for radioactive competitive binding assay. Herein, we designed and synthesized thirteen new P2X7R ligands and determined the in vitro binding potency.
View Article and Find Full Text PDFPostoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial.
Lancet Oncol
September 2024
Edinburgh Cancer Research, CRUK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK; Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK.
Background: Breast-conserving surgery, adjuvant systemic therapy, and radiotherapy are the standard of care for most women with early breast cancer. There are few reports of clinical outcomes beyond the first decade of follow-up of randomised trials comparing breast-conserving surgery with or without radiotherapy. We present a 30-year update of the Scottish Breast Conservation Trial.
View Article and Find Full Text PDFAlbumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma.
Mol Pharm
June 2024
Department of Chemistry, University of Missouri, Columbia, Missouri 65211, United States.
Very late antigen-4 (VLA-4) is a transmembrane integrin protein that is highly expressed in aggressive forms of metastatic melanoma. A small-molecule peptidomimetic, LLP2A, was found to have a low pM affinity binding to VLA-4. Because LLP2A itself does not inhibit cancer cell proliferation and survival, it is an ideal candidate for the imaging and delivery of therapeutic payloads.
View Article and Find Full Text PDFDesign of a New Tc-radiolabeled Cyclo-peptide as Promising Molecular Imaging Agent of CXCR Receptor: Molecular Docking, Synthesis, Radiolabeling, and Biological Evaluation.
Curr Radiopharm
May 2024
Department of Pharmacology and Toxicology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.
Introduction: C-X-C Chemokine receptor type 4 (CXCR4) is often overexpressed or overactivated in different types and stages of cancer disease. Therefore, it is considered a promising target for imaging and early detection of primary tumors and metastasis. In the present research, a new cyclo-peptide radiolabelled with Tc, Tc-Cyclo [D-Phe-D-Tyr-Lys (HYNIC)- D-Arg-2-Nal-Gly-Lys(iPr)], was designed based on the parental LY251029 peptide, as a potential imaging agent of CXCR4-expressing tumors.
View Article and Find Full Text PDFBinding Parameters of [C]MPC-6827, a Microtubule-Imaging PET Radiopharmaceutical in Rodents.
Pharmaceuticals (Basel)
March 2023
Department of Radiology, Wake Forest School of Medicine, Winston Salem, NC 27157, USA.
Impairment and/or destabilization of neuronal microtubules (MTs) resulting from hyper-phosphorylation of the tau proteins is implicated in many pathologies, including Alzheimer's disease (AD), Parkinson's disease and other neurological disorders. Increasing scientific evidence indicates that MT-stabilizing agents protect against the deleterious effects of neurodegeneration in treating AD. To quantify these protective benefits, we developed the first brain-penetrant PET radiopharmaceutical, [C]MPC-6827, for quantification of MTs in rodent and nonhuman primate models of AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!